Breaking news

Explosive Growth In MENA’s Startup Ecosystem

February marked a groundbreaking month for MENA’s startup landscape, with an impressive $494 million raised across 58 deals—almost five times more than last year’s total for the same month. While Saudi Arabia dominated with $250.3 million accrued over 25 deals, the UAE and Egypt followed suit with $203.5 million and $27.5 million respectively.

Debt Financing Dips In February

Unlike January, where debt financing took the bulk of investments, February saw it drop to just 15% of total funding. The exclusion of debt reveals a staggering 371% increase in investment activity, highlighting a promising shift in financial dynamics.

Industry Leaders And Rising Sectors

Fintech emerged as the leading sector, delivering $274 million over 15 deals. Insurtech and logistics took the next spots, with $55 million and $28.5 million respectively. This upswing showcases both sustained interest and escalating financial backing for key tech industries.

Regional Contributions and Gender Disparities

B2B models attracted the most attention in February, garnering $191.6 million through 33 transactions. However, gender disparities remain, as startups led by male founders bagged 87% of the total investment. Despite the progress, this underlines the need for more equitable funding allocations.

For further insights into startup ecosystems, explore how Cyprus is setting new records in global startup growth.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Aretilaw firm
eCredo
Uol
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter